Back to top

Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth

Roth Capital analyst Adam Walsh keeps a Buy rating and $20 price target on shares of Arcturus Therapeutics (ARCT). The Thermo Fisher (TMO) collabor...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Arcturus Therapeutics Holdings Inc. (ARCT)

Thermo Fisher Scientific Inc. (TMO)